Subscribe here for new information from our diverse feeds.
BREAKTHROUGH: Ifakara part of groundbreaking malaria vaccine recommended by WHO
Ifakara Health Institute is privileged to be part of the groundbreaking malaria vaccine known as “RTS,S/ASO1” recommended this week by the World Health Organization (WHO) for children at risk. We at Ifakara consider this as a breakthrough for science, child health and malaria control.
The WHO announced on October 6, 2021 that it recommends widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high malaria transmission. The recommendation is based on results from an ongoing pilot program in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019.
In mid 2000s, IFAKARA evaluated the performance and safety of an earlier version of the vaccine in infants in Tanzania, including feasibility of incorporating this vaccine into the standard immunization programs recommended by the WHO. Conclusions of early studies showed the vaccine had a good safety profile and reduced malaria infections in infants.
In later studies, Ifakara, together with the National Institute for Medical Research (NIMR) in Tanzania also took part in a multi-center study which involved a network of over 10 sites in Africa to evaluate the now approved version of the vaccine, RTS,S.
The vaccine itself, "RTS,S" was created in 1987 by scientists working in the GSK laboratories in the UK. In early 2001, GSK and PATH—with support from the Bill & Melinda Gates Foundation—entered into a partnership to develop the vaccine for infants and young children living in malaria endemic regions in sub-Saharan Africa.
In a quick reaction to the announcement yesterday, a senior researcher at Ifakara who led teams that conducted the RTS,S trials in Tanzania said the latest developments added to a rich profile of the Institute in participating and supporting impactful public health reach programs.
“Ifakara has over 60 years of experience in researching on malaria. We’ve been part of many other impactful studies previously including those culminated in changing policies in Africa and globally on treated mosquito nests and the current first-line malaria drug – ALU,” he said.
Commenting on the announcement, the Director Science at Ifakara, Dr. Fredros Okumu, expressed optimism that the vaccine would have great impact in the fight against malaria. “The RTS,S vaccine will likely have a significant impact in reducing severe malaria and deaths, and in that sense, it is a one-of-a-kind transformative addition for our quest to go towards zero malaria with as few deaths as possible,” he said.
Dr. Okumu underlined that being the very first vaccine against any parasitic disease, and having been evaluated widely by African scientists, it will also likely inspire new interests in this space and hopefully herald greater commitments to malaria control.
“It should be noted though that the benefits will be accrued only if we continue to strengthen our health systems to enable effective vaccine deployment,” he said, stressing: “The WHO endorsement emphasizes that this vaccine, as unique as it is, is only one small component of the arsenal. Countries must continue to focus on other proven interventions, for malaria prevention and case management, as the RTS,S is not itself a silver bullet.”
Commenting on the announcement as well, Head of the Interventions & Clinical Trials Department at Ifakara, Dr. Ally Olotu said: “This great achievement should invigorate the efforts to pursue even more efficacious malaria vaccines. As we push for a speedy deployment of the RTS,S vaccine to more vulnerable infants across Africa, we need to capitalize on this success by advocating for more funding in malaria vaccine development.”
For her part, Head of Health Systems, Impact Evaluation and Policy department at Ifakara, Dr. Sally Mtenga called on stakeholders in the fight against malaria, including policy makers and development partners, to ensure equitable access to malaria vaccines, especially in low-income countries where the social cultural context may impede the optimal uptake of the vaccine. “Equitable access to health care is currently a critical agenda globally… there is need to address the social determinants of community acceptance of the malaria vaccine,” she said.
Ifakara Chief Executive Director, Dr. Honorati Masanja, expressed his Institute’s commitment to continue working with other like-minded partners to find solutions to the most important health problems in the global south and the world at large.
“We advocate for equitable access to various interventions including vaccines that have been approved by WHO. We shall as an institute continue to play a role in developing, testing and validating promising malaria control and other interventions that will improve people's health and wellbeing,” he stressed.
Malaria remains a primary cause of childhood illness and death in sub-Saharan Africa. More than 260 000 African children under the age of five die from malaria annually.